Lynx Investment Advisory Buys 296 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Lynx Investment Advisory grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,501 shares of the biopharmaceutical company’s stock after acquiring an additional 296 shares during the period. Lynx Investment Advisory’s holdings in Gilead Sciences were worth $785,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of GILD. State Street Corp boosted its position in Gilead Sciences by 1.4% in the 3rd quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock valued at $5,044,795,000 after buying an additional 841,776 shares during the period. Wellington Management Group LLP lifted its stake in shares of Gilead Sciences by 50.9% during the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock valued at $2,900,921,000 after buying an additional 11,665,593 shares during the period. FMR LLC increased its position in shares of Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after acquiring an additional 14,680,161 shares in the last quarter. Geode Capital Management LLC grew its holdings in Gilead Sciences by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock valued at $2,302,119,000 after purchasing an additional 574,421 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Gilead Sciences by 3.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 8,002,779 shares of the biopharmaceutical company’s stock worth $739,217,000 after buying an additional 249,804 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

GILD stock opened at $107.08 on Monday. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The firm has a market capitalization of $133.35 billion, a price-to-earnings ratio of 289.41, a PEG ratio of 0.71 and a beta of 0.21. The firm has a 50 day moving average price of $103.68 and a 200-day moving average price of $93.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.95%. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last three months, insiders have sold 302,785 shares of company stock worth $30,503,250. 0.16% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

GILD has been the subject of several research analyst reports. BMO Capital Markets upped their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. The Goldman Sachs Group increased their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Finally, Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $104.52.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.